An inhibitor of RET
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Pralsetinib

Item No. 33181

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
cis-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]-cyclohexanecarboxamide
CAS Number
2097132-94-8
Synonyms
  • BLU-667
Molecular Formula
C27H32FN9O2
Formula Weight
533.6
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: SolubleMethanol: Slightly solubleWater: Slightly soluble
SMILES
C[C@@H](C1=CN=C(N2N=CC(F)=C2)C=C1)NC([C@]3(CC[C@@](C4=NC(C)=CC(NC5=NNC(C)=C5)=N4)([H])CC3)OC)=O
InChi Code
InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27+/m0/s1
InChi Key
GBLBJPZSROAGMF-RWYJCYHVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $53

    Add

    5 mg

    $238

    Add

    10 mg

    $423

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Pralsetinib is an inhibitor of RET (IC50s = 0.4, 0.3, 0.4, and 0.4 nM for wild-type RET, RETV804L, RETV804M, and RETM918T, respectively).1 It is selective for RET over VEGFR2 (IC50 = 35 nM) and a panel of 371 kinases at 300 nM. Pralsetinib also inhibits a fusion protein of coiled-coil domain-containing protein 6 with RET (CCDC6-RET) and autophosphorylation of RET in Ba/F3 cells expressing a fusion protein of kinesin-1 heavy chain with RET (KIF5B-RET; IC50s = 0.4 and 5 nM, respectively). It induces tumor regression in a KIF5B-RET-positive patient-derived xenograft (PDX) mouse model of non-small cell lung cancer (NSCLC) when administered at a dose of 30 mg/kg. Formulations containing pralsetinib have been used in the treatment of metastatic RET-fusion-positive NSCLC.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Subbiah, V., Gainor, J.F., Rahal, R., et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8(7), 836-849 (2018).